Vergelijking

Carbetocin vs. Pasireotid

Twee peptiden naast elkaar — identiteit, bewijsbasis, juridische status en bekende bijwerkingen.

Identiteit

Categorie

Onderzoek (overig)

CAS-nr.

37025-55-1

396091-73-9

Molecuulmassa

geen gegevens

1047.21 g/mol

Halfwaardetijd

0.67 h

geen gegevens

Sequentie

geen gegevens

Werkingsmechanisme

Carbetocin

Carbetocin is an oxytocin receptor agonist with prolonged duration. It triggers a sustained contraction of the uterus after birth, preventing atonic hemorrhage — unlike oxytocin, without a multi-hour infusion.

Pasireotid

Pasireotide binds more broadly than older somatostatin analogs (SSTR1/2/3/5) with particularly high affinity for SSTR5. This suppresses, among others, ACTH release in Cushing's disease and GH release in acromegaly.

Bewijsbasis

Hoogste bewijs

Humane RCT

Studies

waarvan bij mensen

Geregistreerde effecten

Openstaande tegenstrijdigheden

Gedocumenteerde bijwerkingen

Juridische status

Country	Carbetocin	Pasireotid
Duitsland	Op recept	Op recept
Verenigde Staten	Niet goedgekeurd	Op recept

Volledige vermeldingen

Carbetocin

Volledige vermelding →

Pasireotid

Volledige vermelding →

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?: Carbetocin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.
Which peptide is better supported by science, Carbetocin or Pasireotid?: The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.
What is the legal status of Carbetocin and Pasireotid in Germany and the United States?: Duitsland: Carbetocin — Op recept, Pasireotid — Op recept. Verenigde Staten: Carbetocin — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.

Country

Carbetocin

Pasireotid

Duitsland

Op recept

Verenigde Staten

Niet goedgekeurd

Op recept

Frequently asked questions

What is the difference between Carbetocin and Pasireotid?

Carbetocin is classified as "Onderzoek (overig)", while Pasireotid is classified as "Onderzoek (overig)". Carbetocin: Carbetocin is a long-acting synthetic oxytocin analog (half-life ~40 minutes). It prevents postpartum hemorrhage as a single injection. Approved in Canada and the UK among others, NOT in the US. Pasireotid: Pasireotide is a multireceptor somatostatin analog binding to four of the five somatostatin receptors (especially SSTR5). It is approved for Cushing's disease and acromegaly. This page contrasts both neutrally and source-based — with no usage or dosing recommendation.

Which peptide is better supported by science, Carbetocin or Pasireotid?

The highest available evidence level is "Humane RCT" for Carbetocin and "Humane RCT" for Pasireotid. A higher evidence level means more robust data, but says nothing about suitability for an individual. The full body of evidence is on each peptide's own page.

What is the legal status of Carbetocin and Pasireotid in Germany and the United States?

Duitsland: Carbetocin — Op recept, Pasireotid — Op recept. Verenigde Staten: Carbetocin — Niet goedgekeurd, Pasireotid — Op recept. These are factual summaries with source and review date on the individual pages.